drugset / Trial / NCT05856695
Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
NaSingle-groupOpen-labelTreatment
Summary
The current study is intended to be a "proof of concept" to evaluate the potential value of synergy between paclitaxel carboplatin and immunotherapy. If a signal clearly shows superiority over the CASPIAN data , we will have arguments to think that the combination of paclitaxel and carboplatin is more suitable for synergy with immunotherapy than the standard etoposide and carboplatin.
Timeline
- Start
- 2023-11-17
- Primary completion
- 2026-02
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 6 unknown | — |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | — |